KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma
dc.contributor.author | Mandala, M. | |
dc.contributor.author | Yoon, H. | |
dc.contributor.author | Fuchs, C. | |
dc.contributor.author | ÖZGÜROĞLU, Mustafa | |
dc.contributor.author | Bang, Y. | |
dc.contributor.author | Di Bartolomeo, M. | |
dc.contributor.author | Ryu, M. | |
dc.contributor.author | Fornaro, L. | |
dc.contributor.author | Olesinski, T. | |
dc.contributor.author | Caglevic, C. | |
dc.contributor.author | Chung, H. | |
dc.contributor.author | Muro, K. | |
dc.contributor.author | Van Cutsem, E. | |
dc.contributor.author | Elme, A. | |
dc.contributor.author | Thuss-Patience, P. | |
dc.contributor.author | Chau, I. | |
dc.contributor.author | Ohtsu, A. | |
dc.contributor.author | Wang, A. | |
dc.contributor.author | Bhagia, P. | |
dc.contributor.author | Lin, J. | |
dc.contributor.author | Shih, C. | |
dc.contributor.author | Shitara, K. | |
dc.date.accessioned | 2021-03-02T17:41:58Z | |
dc.date.available | 2021-03-02T17:41:58Z | |
dc.identifier.citation | Yoon H., Fuchs C., ÖZGÜROĞLU M., Bang Y., Di Bartolomeo M., Mandala M., Ryu M., Fornaro L., Olesinski T., Caglevic C., et al., "KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma", ESMO 22nd World Congress on Gastrointestinal Cancer, ELECTR NETWORK, 1 - 04 Temmuz 2020, cilt.31 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_4d6a51d4-8c44-48ba-9674-09113c521671 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/4291 | |
dc.identifier.uri | https://doi.org/10.1016/j.annonc.2020.04.065 | |
dc.language.iso | eng | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.title | KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma | |
dc.type | Bildiri | |
dc.contributor.department | Mayo Clinic , , | |
dc.identifier.volume | 31 | |
dc.contributor.firstauthorID | 2284527 |
Bu öğenin dosyaları:
Dosyalar | Boyut | Biçim | Göster |
---|---|---|---|
Bu öğe ile ilişkili dosya yok. |
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Bildiri [64839]